New strategies to improve drug development in carcinoid tumors (Alliance A021202) Bergsland, Emily K. , Geyer, Susan M. , Mahoney, Michelle R. ... - NETRF - - 2020 Abstract - No-Endpoint - Trial-Description-Only - GI - A021202
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Older Adult - CALGB-361006
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Kurtz, David M , Tschetter, Loren K , Allred, Jacob B ... - - Leuk. Lymphoma - 2007 Manuscript - Primary - Primary - Lymphoma - NCCTG-91-78-51
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial Voso, Maria Teresa , Larson, Richard A. , Jones, Dan ... - - Blood Adv - 2020 Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance) Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Ratify (Alliance 10603): Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin Plus Standard Chemotherapy Voso, Maria Teresa , Larson, Richard A. , Prior, Thomas W ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group Witzig, Thomas E. , Geyer, Susan M. , Kurtin, Paul J. ... - - Leuk. Lymphoma - 2008 Manuscript - Primary - Primary - Lymphoma - N9981
